ES2073036T3 - Proteinas b19 de parpovirus humano y particulas de tipo virus, su produccion y su utilizacion en pruebas de diagnostico y vacunas. - Google Patents

Proteinas b19 de parpovirus humano y particulas de tipo virus, su produccion y su utilizacion en pruebas de diagnostico y vacunas.

Info

Publication number
ES2073036T3
ES2073036T3 ES90914243T ES90914243T ES2073036T3 ES 2073036 T3 ES2073036 T3 ES 2073036T3 ES 90914243 T ES90914243 T ES 90914243T ES 90914243 T ES90914243 T ES 90914243T ES 2073036 T3 ES2073036 T3 ES 2073036T3
Authority
ES
Spain
Prior art keywords
proteins
virus
vaccines
human
parpoviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90914243T
Other languages
English (en)
Other versions
ES2073036T5 (es
Inventor
Caroline Sarah Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Leiden
Original Assignee
Universiteit Leiden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19855310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2073036(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Universiteit Leiden filed Critical Universiteit Leiden
Application granted granted Critical
Publication of ES2073036T3 publication Critical patent/ES2073036T3/es
Publication of ES2073036T5 publication Critical patent/ES2073036T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14323—Virus like particles [VLP]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A LAS PROTEINAS DE REVESTIMIENTO VP1 Y VP2 DEL PARPOVIRUS HUMANO B19 Y A LAS PARTICULAS DE TIPO VIRUS QUE CONSISTEN EN VP2 O EN VP1 Y VP2. LA INVENCION COMPRENDE ADEMAS INFORMACION GENETICA EN FORMA DE VECTORES DE EXPRESION RECOMBINANTE QUE CONTIENEN LOS GENES QUE CODIFICAN DICHAS PROTEINAS, Y ORGANISMOS QUE A TRAVES DE MANIPULACION GENETICA UTILIZANDO DICHOS VECTORES HAN ADQUIRIDO LA CAPACIDAD DE PRODUCIR DICHAS PROTEINAS Y/O PARTICULAS. LA INVENCION COMPRENDE ADEMAS LAS UTILIZACIONES DE DICHAS PROTEINAS Y PARTICULAS DE TIPO VIRUS PARA DIAGNOSTICOS O VACUNAS.
ES90914243T 1989-09-14 1990-09-11 Proteinas b19 de parpovirus humano y particulas de tipo virus, su produccion y su utilizacion en pruebas de diagnostico y vacunas. Expired - Lifetime ES2073036T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8902301A NL8902301A (nl) 1989-09-14 1989-09-14 Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins.
NL8902301 1989-09-14

Publications (2)

Publication Number Publication Date
ES2073036T3 true ES2073036T3 (es) 1995-08-01
ES2073036T5 ES2073036T5 (es) 2006-08-01

Family

ID=19855310

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90914243T Expired - Lifetime ES2073036T5 (es) 1989-09-14 1990-09-11 Proteinas b19 de parpovirus humano y particulas de tipo virus, su produccion y su utilizacion en pruebas de diagnostico y vacunas.

Country Status (7)

Country Link
EP (1) EP0491824B2 (es)
AT (1) ATE122395T1 (es)
DE (1) DE69019359T3 (es)
DK (1) DK0491824T4 (es)
ES (1) ES2073036T5 (es)
NL (1) NL8902301A (es)
WO (1) WO1991004330A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2755817B2 (ja) * 1988-11-14 1998-05-25 アメリカ合衆国 パルボウイルスキャプシド
ATE234925T1 (de) * 1991-07-19 2003-04-15 Univ Queensland Impfstoffe gegen papillomavirus
ES2048646B1 (es) * 1992-04-15 1994-10-01 Ercros Sa Procedimiento para la obtencion de la proteina vp2 del virus de la peste equina africana (ahsv)
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
CA2175256A1 (en) 1993-10-28 1995-05-04 Andrea Kern Adeno-associated virus - its diagnostic use with early abortion
AU5103396A (en) * 1995-03-08 1996-09-23 Klaus Hedman Method for the diagnosis of injections
ES2282998T3 (es) * 1996-01-02 2007-10-16 Institut Pasteur Pseudo-particularmente viricas recombinadas y aplicaciomnes vacunales y antitumorales.
FR2771751B1 (fr) 1997-12-03 2000-05-26 Assist Publ Hopitaux De Paris Erythrovirus et ses applications
US6238860B1 (en) 1998-11-05 2001-05-29 Dyax Corp. Binding moieties for human parvovirus B19
US6743772B1 (en) 1998-11-24 2004-06-01 Kristina Broliden Use of parovirus capsid particles in the inhibition of cell proliferation and migration
US6818612B2 (en) 1998-11-24 2004-11-16 Kristina Broliden Use of parvovirus capsid particles in the inhibition of cell proliferation and migration
SE520177C2 (sv) * 1998-11-24 2003-06-03 Kristina Broliden Användning av tomma, icke-infektiösa, rekombinanta parvoviruskapsidpartiklar, eller P-antigenblockerande delar därav, för framställning av läkemedel för ihibering av hematopoietiska stamceller
CZ308201B6 (cs) 2001-06-28 2020-02-26 Grifols Worldwide Operations Limited Diagnostické zkoušky pro parvovirus B19
EP1785433A4 (en) * 2004-07-01 2008-10-01 Tokyo Inst Tech VIRUS PARTICULAR CONSTRUCT AND METHOD FOR THEIR EDUCATION UNDER PHYSIOLOGICAL CONDITIONS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971793A (en) * 1988-05-09 1990-11-20 Boyce Thompson Institute For Plant Research, Inc. Subunit canine parvovirus vaccine

Also Published As

Publication number Publication date
ES2073036T5 (es) 2006-08-01
WO1991004330A1 (en) 1991-04-04
ATE122395T1 (de) 1995-05-15
DK0491824T4 (da) 2006-05-08
DE69019359T3 (de) 2006-09-07
EP0491824A1 (en) 1992-07-01
NL8902301A (nl) 1991-04-02
DE69019359D1 (de) 1995-06-14
EP0491824B2 (en) 2006-04-12
EP0491824B1 (en) 1995-05-10
DE69019359T2 (de) 1995-10-12
DK0491824T3 (da) 1995-07-17

Similar Documents

Publication Publication Date Title
ES2073036T3 (es) Proteinas b19 de parpovirus humano y particulas de tipo virus, su produccion y su utilizacion en pruebas de diagnostico y vacunas.
Smith et al. Conserved surface-exposed K/RXK/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense
NL189092C (nl) Hybride menselijke leukocytinterferons, dubbelstrengs dna dat hiervoor codeert, expressievector, transformant micro-organisme, werkwijzen ter bereiding daarvan en farmaceutisch preparaat.
IT1153265B (it) Polipeptidi contenenti la sequenza degli amminoacidi dell'interferone umano immune (interferone umano gamma), relativi veicoli di espressione, loro procedimento di preparazione, composizioni farmaceutiche contenenti tali polipeptidi
SE9004010D0 (sv) Viralt medel
DE69527049D1 (de) Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte
GB2255777B (en) Indicator cells and recombinant retroviruses for use in the detection of gene sequences
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
ATE209686T1 (de) Adenovirale vektoren tierischen ursprungs und ihre verwendung bei der gentherapie
MX6339E (es) Metodo para elaborar dentro de un huesped bacteriano y excretar a traves de la membrana de la celula huesped,una proteina o un polipeptido seleccionados
FI97809B (fi) Rekombinantti-DNA-molekyyli, joka koodaa kudosperäisen plasminogeenin aktivaattorin (TPA) analogia
DK43890D0 (da) Nucleinsyre, vektorer og celler indeholdende den, derudfra fremstillede produkter og disses anvendelse
SE9002589L (sv) Neutrofil-aktiverande peptid-2
HUP0003563A2 (hu) Aminoterminálisa felől csonkolt MCP-2 mint kemokinantagonista
ES2094907T3 (es) Secuencias de adn que codifican para caracteristicas de virulencia de -s(streptococcus suis) y partes del mismo, polipeptidos y anticuerpos derivados de este y su uso para la diagnosis y la proteccion contra la infeccion por -s(s. suis) en mamiferos, incluyendo el ser humano.
DE3853139D1 (de) Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
ATE20590T1 (de) Chemokinesine und chemotaxine aus leukozyten und entzuendeten geweben: natuerliche mediationsproteine fuer umkehrbare foerderung von willkuerlichen und gerichteten bewegungen (chemokinesis und chemotaxis) und fuer akkumulation von spezifischen leukozytarten; verfahren zu ihrer biotechnischen herstellung und pharmazeutische zusammensetzungen.
PT789764E (pt) Nova familia de inibidores de protease e outras substancias biologicas activas
ATE166390T1 (de) Anti-katze immundefiziensvirus (fiv) impfstoffe
NZ242955A (en) Dna containing gene sequences corresponding to sequences causing alzheimers disease, detection, recombinant yeast with such code
DE69211770T2 (de) Haarbehandlungsmittel mit Perfluoropolyethern und einem Perlglanzmittel
ZA898479B (en) Injury-stimulated dna sequence from solanum tuberosum,and use thereof
FR2636953B1 (fr) Nouveaux polypeptides produits par des lymphocytes humains, genes codant pour ces polypeptides et applications pharmaceutiques et biologiques
Anionwu Assessing Genetic Risks: Implications for Health and Social Policy
KR920009981A (ko) 아데노-관련된 바이러스 타입 2에 의해 암호화되는 rep 유전자의 항바이러스 활성

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 491824

Country of ref document: ES